The Scottish Medicines Consortium have today announced that Niraparib (a PARP inhibitor) will be available as a maintenance treatment for women with relapsed ovarian cancer who do not have a BRCA mutation.

This enables more women in Scotland access to PARP inhibitors and allows them greater choice in how their cancer is treated.

Ovacome will continue to represent the views of our members to SMC and NICE as we advocate for broader treatment availability across the UK, for women with all types of ovarian cancer.